These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 22896656

  • 1. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
    Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM.
    Clin Cancer Res; 2012 Nov 01; 18(21):5911-23. PubMed ID: 22896656
    [Abstract] [Full Text] [Related]

  • 2. An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade.
    Li L, Li X, Han X, Yang T, Fu J, Zhang Y, Gou W.
    Oncol Rep; 2014 Sep 01; 32(3):943-50. PubMed ID: 24968896
    [Abstract] [Full Text] [Related]

  • 3. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
    Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, Ju Z, Hennessy BT, Slingerland JM.
    Breast Cancer Res Treat; 2011 Jul 01; 128(1):69-78. PubMed ID: 20669046
    [Abstract] [Full Text] [Related]

  • 4. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
    Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM.
    Clin Cancer Res; 2018 Oct 01; 24(19):4874-4886. PubMed ID: 29959144
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
    Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F.
    Mol Cancer Ther; 2012 Jul 01; 11(7):1528-38. PubMed ID: 22452946
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ, Im SA, Oh DY, Elvin P, Kim HP, Yoon YK, Min A, Song SH, Han SW, Kim TY, Bang YJ.
    Mol Cancer Ther; 2013 Jan 01; 12(1):16-26. PubMed ID: 23144237
    [Abstract] [Full Text] [Related]

  • 7. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
    Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F.
    Clin Cancer Res; 2016 Feb 15; 22(4):935-47. PubMed ID: 26482043
    [Abstract] [Full Text] [Related]

  • 8. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK, Ribas R, Pancholi S, Nikitorowicz-Buniak J, Simigdala N, Dowsett M, Johnston SR, Martin LA.
    PLoS One; 2016 Feb 15; 11(6):e0157397. PubMed ID: 27308830
    [Abstract] [Full Text] [Related]

  • 9. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L, Shay C, Zhao X, Xiong Y, Wang X, Teng Y.
    J Hematol Oncol; 2019 Dec 05; 12(1):132. PubMed ID: 31805962
    [Abstract] [Full Text] [Related]

  • 10. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
    Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS.
    Clin Transl Sci; 2016 Dec 05; 9(6):293-301. PubMed ID: 27766744
    [Abstract] [Full Text] [Related]

  • 11. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
    Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM.
    Clin Cancer Res; 2009 May 15; 15(10):3396-405. PubMed ID: 19451593
    [Abstract] [Full Text] [Related]

  • 12. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM.
    Cancer Res; 2005 Feb 15; 65(4):1459-70. PubMed ID: 15735034
    [Abstract] [Full Text] [Related]

  • 13. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
    Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ.
    J Thorac Oncol; 2013 Mar 15; 8(3):270-8. PubMed ID: 23399957
    [Abstract] [Full Text] [Related]

  • 14. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
    Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, Eckhardt SG, Elvin P, Gao D, Messersmith WA.
    Clin Cancer Res; 2010 Aug 15; 16(16):4165-77. PubMed ID: 20682712
    [Abstract] [Full Text] [Related]

  • 15. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.
    Mol Cancer Ther; 2015 Sep 15; 14(9):2035-48. PubMed ID: 26116361
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Ishii Y, Papa L, Bahadur U, Yue Z, Aguirre-Ghiso J, Shioda T, Waxman S, Germain D.
    Clin Cancer Res; 2011 Apr 15; 17(8):2292-300. PubMed ID: 21292820
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.
    Breast Cancer Res; 2014 May 05; 16(3):R45. PubMed ID: 24887236
    [Abstract] [Full Text] [Related]

  • 18. Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.
    Wang L, Yu X, Dong J, Meng Y, Yang Y, Wang H, Wang C, Zhang Y, Zhao Y, Zhao J, Wang H, Lu C, Li B.
    Biochem Biophys Res Commun; 2016 Oct 21; 479(3):563-570. PubMed ID: 27666484
    [Abstract] [Full Text] [Related]

  • 19. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
    Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP.
    Mol Cancer Ther; 2010 Jun 21; 9(6):1629-37. PubMed ID: 20484016
    [Abstract] [Full Text] [Related]

  • 20. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
    Han S, Meng Y, Tong Q, Li G, Zhang X, Chen Y, Hu S, Zheng L, Tan W, Li H, Chen Y, Zhang G, Li B, Guo Y.
    MAbs; 2014 Jun 21; 6(2):403-8. PubMed ID: 24492292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.